CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
timolol/dorzolamide combinationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00832377
NCT00832377Phase 2Completed
CompareCT.gov

Prospective, Open-label, Single-arm Study to Evaluate Efficacy and Safety of Combination Therapy of Timolol and Dorzolamide (COSOPT) as Initial Treatment for Patients With Normal Tension Glaucoma

Merck Sharp & Dohme LLC·interventional·Posted Jan 30, 2009·Updated Sep 29, 2017

In Brief

A Phase 2 clinical trial evaluating timolol/dorzolamide combination for Glaucoma. Completed, enrolled 37 participants.

Detailed Summary

A study to evaluate the effect of the 12-week treatment with timolol/dorzolamide combination eyedrops (COSOPT) on decrease in intraocular pressure (IOP) at 2 hours after the study drug administration

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 30, 2009
Enrollment StartApr 24, 2009
Primary CompletionMar 12, 2010
Study CompletionMar 26, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.4 years ago

Interventions

timolol/dorzolamide combinationdrug

Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks